A Phase I Double-Blind, Randomised, Placebo-Controlled, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of UE2343 in Healthy Subjects

Trial Profile

A Phase I Double-Blind, Randomised, Placebo-Controlled, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of UE2343 in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 04 May 2017

At a glance

  • Drugs UE 2343 (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Actinogen Medical
  • Most Recent Events

    • 28 Apr 2017 Results from this trial have been published in the British Journal of Pharmacology in February 2017, according to an Actinogen Medical media release.
    • 25 Nov 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 29 Sep 2015 Results were published in an Actinogen media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top